Medicare HSAs May Compel Drug Industry To Rethink Position On OTCs
This article was originally published in The Tan Sheet
Executive Summary
The growth of health savings accounts could force pharmaceutical companies to rethink their approach to OTC switches and consumer marketing, medical economist J.D. Kleinke told the Pharmaceutical Research & Manufacturers of America